{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-087545","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.359761+00:00","generated_at":"2026-05-31T10:27:05.912906+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acurx Q2 net loss $4.1M, cash $6.4M; FDA confirms Phase 3 readiness for ibezapolstat","bullets":["Net loss of $4.1M ($0.26/diluted share) for Q2 2024 vs. $3.4M ($0.28) in Q2 2023.","Cash $6.4M at June 30, 2024, down from $7.5M at Dec 31, 2023; raised $0.3M via ATM in Q2.","R&D expenses $1.8M (Q2 2024) vs $1.7M (Q2 2023); G&A $2.3M vs $1.7M.","Completed End-of-Phase 2 FDA meeting; agreement on Phase 3 and NDA plan for ibezapolstat (IBZ) for C. difficile.","USPTO granted IBZ patent expiring June 2042 covering reduced recurrence and microbiome health."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-087545","json":"https://secwatch.observer/filing/0001104659-24-087545.json","markdown":"https://secwatch.observer/filing/0001104659-24-087545.md","text":"https://secwatch.observer/filing/0001104659-24-087545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465924087545/0001104659-24-087545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465924087545/tm2421278d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:27:05.912906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}